These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14614031)

  • 61. Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.
    Kobayashi T; Niioka T; Miura M; Takahashi N
    Ann Hematol; 2016 Dec; 95(12):2087-2088. PubMed ID: 27595758
    [No Abstract]   [Full Text] [Related]  

  • 62. DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma?
    de la Rubia J; Such E
    Leuk Lymphoma; 2010 Nov; 51(11):1960-1. PubMed ID: 21077744
    [No Abstract]   [Full Text] [Related]  

  • 63. M(yeloma)IXing up T maintenance.
    Harrison SJ; Khot A
    Blood; 2012 Jan; 119(1):1-2. PubMed ID: 22223816
    [No Abstract]   [Full Text] [Related]  

  • 64. [Thalidomide].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():316-20. PubMed ID: 30615389
    [No Abstract]   [Full Text] [Related]  

  • 65. Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide.
    Tewari P; Kenny E; Staines A; Chanock S; Browne P; Lawler M
    Blood; 2009 May; 113(22):5691-2. PubMed ID: 19478055
    [No Abstract]   [Full Text] [Related]  

  • 66. Toward optimizing pomalidomide therapy in MM patients.
    Podar K
    Blood; 2015 Jun; 125(26):3968-9. PubMed ID: 26113530
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Thalidomide in patients with multiple myeloma and renal failure.
    Fakhouri F; Guerraoui H; Presne C; Peltier J; Delarue R; Muret P; Knebelmann B
    Br J Haematol; 2004 Apr; 125(1):96-7. PubMed ID: 15015981
    [No Abstract]   [Full Text] [Related]  

  • 68. AEterna reports on its phase II trial of neovastat.
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):3-4. PubMed ID: 12113128
    [No Abstract]   [Full Text] [Related]  

  • 69. Thalidomide for myeloma: still here?
    Dimopoulos MA; Kastritis E
    Lancet Haematol; 2018 Oct; 5(10):e439-e440. PubMed ID: 30290901
    [No Abstract]   [Full Text] [Related]  

  • 70. Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002.
    Lippman SM; Hong WK
    Clin Cancer Res; 2002 Feb; 8(2):305-13. PubMed ID: 11839646
    [No Abstract]   [Full Text] [Related]  

  • 71. Correspondence re: M. R. Teixeira et al., Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res., 56: 855-859, 1996.
    Cline JM
    Cancer Res; 1996 Nov; 56(21):5098. PubMed ID: 8895770
    [No Abstract]   [Full Text] [Related]  

  • 72. Thalidomide metabolism and hydrolysis: mechanisms and implications.
    Lepper ER; Smith NF; Cox MC; Scripture CD; Figg WD
    Curr Drug Metab; 2006 Aug; 7(6):677-85. PubMed ID: 16918319
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Synthesis and teratologic examination of various thalidomide metabolites].
    Meise W; Köhler F
    Pharmazie; 1972 Jun; 27(6):418-9. PubMed ID: 5082274
    [No Abstract]   [Full Text] [Related]  

  • 74. [Action of imidazole on the first metabolites of thalidomide. Study of the disruption of the phthalimide nucleus].
    Champy-Hatem S
    Arzneimittelforschung; 1965 May; 15(5):508-12. PubMed ID: 5898291
    [No Abstract]   [Full Text] [Related]  

  • 75. Correspondence re: J. M. Yuhas and A. P. Li. Growth fraction as the major determinant of multicellular tumor spheroid growth rates. Cancer Res., 38: 1528-1532, 1978.
    Curphey TJ
    Cancer Res; 1984 Feb; 44(2):866-8. PubMed ID: 6692386
    [No Abstract]   [Full Text] [Related]  

  • 76. Protein abnormalities in serum and urine in patients with multiple myeloma.
    PAGET M
    J Sci Med Lille; 1955 May; 73(5):217-33. PubMed ID: 14392658
    [No Abstract]   [Full Text] [Related]  

  • 77. [Lipoprotein disturbances in myeloma patients].
    WEISMANN-NETTER R; HIRSCH-MARIE H
    Presse Med (1893); 1958 Nov; 66(80):1787-8. PubMed ID: 13614321
    [No Abstract]   [Full Text] [Related]  

  • 78. [Myeloma protein in urine; a new, rapid method of detection].
    EFFERSOE P; TIDSTROM B
    Nord Med; 1957 Feb; 57(8):290-3. PubMed ID: 13419140
    [No Abstract]   [Full Text] [Related]  

  • 79. [Urinary organic acids in myeloma].
    HALPERN MJ; RELVAS ME; da COSTA S
    Gaz Med Port; 1960; 13():591-6. PubMed ID: 13710920
    [No Abstract]   [Full Text] [Related]  

  • 80. [Multiple myeloma with hyperammonemia].
    Izumi T
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):446-8. PubMed ID: 9851186
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.